Neuroendocrine Tumors - Patient Reported Outcomes
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Clinical Trials Related to Neuroendocrine Tumors
Related studies linked through entity extraction aliases.
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
- Status
- RECRUITING
- Phase
- PHASE1
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
- Status
- COMPLETED
- Phase
- NA
Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study
- Status
- COMPLETED
- Phase
- N/A
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Combination Immunotherapy in Rare Cancers Under InvesTigation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
- Status
- RECRUITING
- Phase
- PHASE2
Spanish Series of Patients Treated With the Radionuclide Lutetium177
- Status
- RECRUITING
- Phase
- N/A
Optimising Molecular Radionuclide Therapy
- Status
- COMPLETED
- Phase
- N/A
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
- Status
- WITHDRAWN
- Phase
- PHASE2
Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
68Ga-DOTA-TATE PET/CT Imaging in NETs
- Status
- RECRUITING
- Phase
- PHASE3
Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors
- Status
- WITHDRAWN
- Phase
- PHASE2
Expanded Access Program of Surufatinib
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA